Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

nd uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Revenue
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... September 18, 2014 Leatherwood Plastics ... listed material, to stay competitive in the semiconductor, ... high-performance materials ultimately impact product quality and productivity, ... owner. , Established in 1980 in Lewisville, TX, ... many fabricators have left the business. Much of ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... April 7 Transgenomic, Inc. (OTC Bulletin Board: TBIO), ... completed a licensing option with the Dana-Farber Cancer Institute, ... Cold-PCR. This variation of the standard PCR technology ... was invented at Dana-Farber by Dr. Mike Makrigiorgos who ...
... WellGen, Inc. today announced that Dr. Roderick (Roddy) ... Executive Officer. Dr. Carter, 45, takes over ... Chief Executive Officer. Mr. Bertoldi will continue in ... Financial Officer of Amphion Innovations plc (LSE: AMP), a ...
... Inc. today announced that it has secured $38 million ... formation in 2004, the company has raised $92 million ... financing round, which consists of two tranches, was led ... pro rata participation of existing investors Apax Partners, Clarus ...
Cached Biology Technology:Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 2Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 3Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 4Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc. 2Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc. 3Aerovance Secures $38 Million in Equity Financing 2Aerovance Secures $38 Million in Equity Financing 3
(Date:9/18/2014)... ever starts a "frequent flyers" program, fruit flies surely ... laboratory has hosted increasing numbers of fruit fly research ... station in April, and another is scheduled launch to ... to launch in December. , Fruit flies are biomedical ... in space. Model organisms can reveal the basis for ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... -- Weill Cornell Medical College and the Columbia University ... Mortimer D. Sackler, M.D. Prize for Distinguished Achievement in ... Dr. Fernando Nottebohm for his seminal work in songbirds ... Dr. Nottebohm is currently the Dorothea L. Leonhardt ...
... but in an infectious disease, it is insidious. Witness tuberculosis, ... before bursting forth into infection. TB,s stealthy nature has made ... to control it. The World Health Organization estimates that a ... a study led by Stanford scientists has provided new insights ...
... sends the human immune system into overdrive it can ... and thrive inside our digestive system. New research suggests ... significant role in triggering the innate immune system to stay ... in the face of an infection. But exactly how ...
Cached Biology News:Sackler Prize awarded to pioneering neuroscientist 2Sackler Prize awarded to pioneering neuroscientist 3Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 2Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 3Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 4Stress wrecks intestinal bacteria, could keep immune system on idle 2
... The LabChip 3000 drug discovery system ... cell-based assays. Using LabChip technology, ... in a serial, continuous flow fashion. ... quality of results exceeds what is ...
...
...
...
Biology Products: